Поиск
Закладки
Озвучить текст Озвучить книгу
Изменить режим чтения
Изменить размер шрифта
Оглавление
Для озвучивания и цитирования книги перейдите в режим постраничного просмотра.
Диагностика и лечение волчаночного нефрита

Список литературы

  1. Rahman A., Isenberg D.A. Systemic lupus erythematosus. N Engl J Med 2008;358:929-939.
  2. Tsokos G.C. Systemic lupus erythematosus. N Engl J Med 2011;365:2110-2121.
  3. Weening J.J., D’Agati V.D., Schwartz M.M., et al. The classification of glomerulonephritis in systemic lupus erythematosus revisited. Kidney Int 2004;65:521-530.
  4. Rovin B.H., Caster D.J., Cattran D.C., Gibson K.L., Hogan J.J., et al. Management and treatment of glomerular diseases (part 2): conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference Kidney Int 2019;95:281-295. doi: 10.1016/j.kint.2018.11.008
  5. Rekvig O.P., van der Vlag J. The pathogenesis and diagnosis of systemic lupus erythematosus: still not resolved. Semin Immunopathol 2014;3:301-311. doi: 10.1007/s00281-014-0428-6
  6. Mohan C., Putterman C. Genetics and pathogenesis of systemic lupus erythematosus and lupus nephritis. Nat Rev Nephrol 2015;11:329-341. doi: 10.1038/nrneph.2015.33
  7. Attar S.M., Koshak E.A. Medical conditions associated with a positive anti-double- stranded deoxyribonucleic acid. Saudi Med J 2010;31:781-787.
  8. Sengupta M., Morel L. Lupus at the molecular level. Protein Cell 2011;2:941-943. doi: 10.1007/s13238-011-1123-1
  9. Danchenko N., Satia J.A., Anthony M.S. Epidemiology of systemic lupus erythematosus: a comparison of worldwide disease burden. Lupus 2006 15(5);308- 318. doi: 10.1191/0961203306lu2305xx
  10. Aringer M., Costenbader K., Daikh D., Brinks R., Mosca M., et al. 2019 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus. Arthritis Rheum 2019;71(9):1400-1412. doi: 10.1002/art.40930
  11. Bombardier C., Gladman D.D., Urowitz M.B., Caron D., Chang D.H. Committee on Prognosis Studies in SLE Derivation of the SLEDAI: a disease activity index for lupus patients. Arthritis Rheum 1992;35:630-640. doi: 10.1002/art.1780350606
  12. Gladman D.D., Ibanez D., Urowitz M.B. Systemic lupus erythematosus disease activity index 2000. J Rheumatol 2002;29:288-291.
  13. Petri M., Kim M.Y., Kalunian K.C., Grossman J., Hahn B.H., Sammaritano L.R., et al. OC-SELENA Trial. Combined oral contraceptives in women with systemic lupus erythematosus. N Engl J Med 2005;353(24):2550-2558.
  14. Bajema I.M., Wilhelmus S., Alpers C.E., Bruijn J.A., Colvin R.B., et al. Revision of the International Society of Nephrology/Renal Pathology Society classification for lupus nephritis: clarification of definitions, and modified National Institutes of Health activity and chronicity indices. Kidney Int 2018;93:789-796.
  15. Petri M, Orbai AM, Alarcon GS, et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum 2012;64:2677-2686
  16. Bertsias G.K., Pamfil C., Fanouriakis A., Boumpas D.T. Diagnostic criteria for systemic lupus erythematosus: has the time come? Nat Rev Rheumatol 2013;9:687- 94.
  17. Almaani S., Meara A., Rovin B.H. Update on Lupus Nephritis. Clin J Am Soc Nephrol 2017;12(5):825-835. doi: 10.2215/CJN.05780616.
  18. Schwartz M.M., Korbet S.M., Lewis E.J., et al. The prognosis and pathogenesis of severe lupus glomerulonephritis. Nephrol Dial Transplant. 2008;23:1298–1306.
  19. Haring C.M., Rietveld A., van den Brand J.A., et al. Segmental and global subclasses of class IV lupus nephritis have similar renal outcomes. J Am Soc Nephrol 2012;23:149-154.
  20. Хроническая болезнь почек (ХБП). Клинические рекомендации. https://rusnephrology.org/wp-content/uploads/2020/12/CKD_final.pdf
  21. Kidney Disease: Improving Global Outcomes (KDIGO) Glomerulonephritis Work Group. KDIGO Clinical Practice Guideline for Glomerulonephritis. Kidney Int Suppl 2012; 2:139-274.
  22. Бирюкова Л.С., Захарова Е.В., Кальянова Е.В. Клинические практические рекомендации KDIGO по лечению гломерулонефритов (перевод на русский язык под ред. Е.В. Захаровой). Нефрология и диализ 2014;1(приложение 1):1- 163.
  23. Bertsias GK, Tektonidou M, Amoura Z, et al. Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. Ann Rheum Dis 2012;71(11):1771-1782. doi: 10.1136/annrheumdis-2012-201940
  24. Захарова Е.В. Совместные рекомендации Европейской лиги по борьбе с ревматизмом и Европейской почечной ассоциации-Европейской ассоциации диализа и трансплантации по ведению волчаночного нефрита у взрослых и детей (перевод на русский язык). Нефрология и диализ 2012;14(4):206-222.
  25. Козловская Н.Л., Моисеев С.В., Новиков П.И. Лечение волчаночного нефрита: новые рекомендации EULAR/ERA-EDTA. Клиническая фармакология и терапия 2013;22(1):62-68.
  26. Козловская Н.Л., Захарова Е.В. Системная красная волчанка. Нефрология. Национальное руководство краткое издание, ГЭОТАР-Медиа, Москва. 2014:269-287.
  27. Козловская Н.Л., Захарова Е.В., Коротчаева Ю.В. Гломерулонефрит при системной красной волчанке. Национальные клинические рекомендации по лечению гломерулонефритов. Под ред. Е.М. Шилова. 2015. М. «Белый Ветер»:177-200.
  28. Dall’Era M, Cisternas MG, Smilek DE, et al. Predictors of long-term renal outcome in lupus nephritis trials: lessons learned from the Euro-Lupus Nephritis cohort. Arthritis Rheumatol 2015;67:1305-1313.
  29. Ugolini-Lopes MR, Seguro LPC, Castro MXF, et al. Early proteinuria response: a valid real-life situation predictor of long-term lupus renal outcome in an ethnically diverse group with severe biopsy-proven nephritis? Lupus Sci Med 2017;4:e000213
  30. Tamirou F, Lauwerys BR, Dall'Era M, et al. A proteinuria cut-off level of 0.7 g/day after 12 months of treatment best predicts long-term renal outcome in lupus nephritis: data from the MAINTAIN Nephritis Trial. Lupus Sci Med 2015;2:e000123. doi: 10.1136/lupus-2015-000123
  31. Birmingham D.J., Irshaid F., Nagaraja H.N., Zou X., Tsao B.P., et al. The complex nature of serum C3 and C4 as biomarkers of lupus renal flare. Lupus 2010;19:1272
  32. Jeong S, Yang D, Lee W, Kim GT, Kim HS, et al. Diagnostic value of screening enzyme immunoassays compared to indirect immunofluorescence for anti-nuclear antibodies in patients with systemic rheumatic diseases: A systematic review and meta-analysis. Semin Arthritis Rheum 2018;48(2):334-342. doi: 10.1016/j.semarthrit.2018.01.011. PMID: 29609799
  33. Yang XW, Tan Y, Yu F, et al. Combination of anti-C1q and anti-dsDNA antibodies is associated with higher renal disease activity and predicts renal prognosis of patients with lupus nephritis. Nephrol Dial Transplant 2012;27:3552-3559.
  34. Rijnink EC, Teng YKO, Kraaij T, et al. Validation of the Systemic Lupus International Collaborating Clinics classification criteria in a cohort of patients with full house glomerular deposits. Kidney Int 2018;93:214-220.
  35. Wang H, Ren YL, Chang J, Gu L, Sun LY. A Systematic Review and Meta-analysis of Prevalence of Biopsy-Proven Lupus Nephritis. Arch Rheumatol 2017;33(1):17-25. doi: 10.5606/ArchRheumatol.2017.6127. PMID: 29900975; PMCID: PMC5864167
  36. Fanouriakis A, Kostopoulou M, Cheema K, et al. 2019 Update of the Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERAEDTA) recommendations for the management of lupus nephritis. Ann Rheum Dis 2020;79(6):713-723.
  37. Козловская НЛ, Соловьев СК, Асеева ЕА, и др. Обновленные рекомендации EULAR/ERA–EDTA 2019 г. по терапии волчаночного нефрита. Комментарии экспертов. Часть I. Современная ревматология 2020;14(4):7–15. doi: 10.14412/1996-7012- 2020-4-7-15
  38. van Vollenhoven RF, Mosca M, Bertsias G, Isenberg D, Kuhn A, et al. Treat-to-target in systemic lupus erythematosus: recommendations from an international task force. Ann Rheum Dis 2014;73(6):958-967.
  39. van Vollenhoven R, Voskuyl A, Bertsias G, Aranow C, Aringer M, et al. A framework for remission in SLE: consensus findings from a large international task force on definitions of remission in SLE (DORIS). Ann Rheum Dis 2017;76(3):554- 561. doi: 10.1136/annrheumdis-2016-209519
  40. Ruiz-Irastorza G, Ramos-Casals M, Brito-Zeron P, et al. Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review. Ann Rheum Dis 2010;69:20-28.
  41. Singh JA, Hossain A, Kotb A, et al. Risk of serious infections with immunosuppressive drugs and glucocorticoids for lupus nephritis: a systematic review and network meta-analysis. BMC Med 2016;14:137-149. doi: 10.1186/s12916-016-0673-8
  42. Sciascia S, Mompean E, Radin M, et al. Rate of adverse effects of medium- to high- dose glucocorticoid therapy in systemic lupus erythematosus: a systematic review of randomized control trials. Clin Drug Investig 2017;37:519-524.
  43. Ruiz-Irastorza G, Ugarte A, Saint-Pastou Terrier C, et al. Repeated pulses of methylprednisolone with reduced doses of prednisone improve the outcome of class III, IV and V lupus nephritis: an observational comparative study of the Lupus- Cruces and lupus-Bordeaux cohorts. Autoimmun Rev 2017;16:826-832
  44. Ruiz-Arruza I, Lozano J, Cabezas-Rodriguez I, et al. Restrictive use of oral glucocorticoids in systemic lupus erythematosus and prevention of damage without worsening long-term disease control: an observational study. Arthritis Care Res 2018;70:582-591.
  45. Houssiau FA, Vasconcelos C, D'Cruz D, et al. Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high- dose intravenous cyclophosphamide. Arthritis Rheum 2002;46(8):2121-2131.
  46. Appel GB, Contreras G, Dooley MA, et al. Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. J Am Soc Nephrol 2009;20(5):1103-1012.
  47. Houssiau FA, Vasconcelos C, D'Cruz D, et al. The 10-year follow-up data of the Euro-Lupus Nephritis Trial comparing low-dose and high-dose intravenous cyclophosphamide. Ann Rheum Dis 2010;69(1):61-64.
  48. Walsh M, Solomons N, Lisk L, et al. Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis with poor kidney function: a subgroup analysis of the Aspreva lupus management study. Am J Kidney Dis 2013;61:710-715.
  49. Rijnink EC, Teng YKO, Wilhelmus S, et al. Clinical and histopathologic characteristics associated with renal outcomes in lupus nephritis. Clin J Am Soc Nephrol 2017;12:734-743.
  50. Miyasaka N, Kawai S, Hashimoto H. Efficacy and safety of tacrolimus for lupus nephritis: a placebo-controlled double-blind multicenter study. Mod Rheumatol 2009;19:606-615.
  51. Uchino A, Tsukamoto H, Nakashima H, et al. Tacrolimus is effective for lupus nephritis patients with persistent proteinuria. Clin Exp Rheumatol 2010;28:6-12.
  52. Chen W, Tang X, Liu Q, et al. Short-term outcomes of induction therapy with tacrolimus versus cyclophosphamide for active lupus nephritis: a multicenter randomized clinical trial. Am J Kidney Dis 2011;57:235-244.
  53. Lee YH, Lee HS, Choi SJ, et al. Efficacy and safety of tacrolimus therapy for lupus nephritis: a systematic review of clinical trials. Lupus 2011;20:636-640.
  54. Ikeuchi H, Hiromura K, Takahashi S, et al. Efficacy and safety of multi-target therapy using a combination of tacrolimus, mycophenolate mofetil and a steroid in patients with active lupus nephritis. Mod Rheumatol 2014;24:618-625.
  55. Kasitanon N, Boripatkosol P, Louthrenoo W. Response to combination of mycophenolate mofetil, cyclosporin A and corticosteroid treatment in lupus nephritis patients with persistent proteinuria. Int J Rheum Dis 2018;21:200-207.
  56. Mok CC, To CH, Yu KL, et al. Combined low-dose mycophenolate mofetil and tacrolimus for lupus nephritis with suboptimal response to standard therapy: a 12 - month prospective study. Lupus 2013;22:1135-1141.
  57. Liu Z, Zhang H, Liu Z, et al. Multitarget therapy for induction treatment of lupus nephritis: a randomized trial. Ann Intern Med 2015;162:18-26.
  58. Melander, C, Sallée, M, Trolliet, P. Rituximab in severe lupus nephritis: Early B-cell depletion affects long-term renal outcome. Clin J Am Soc Nephrol 2009;4:579-587.
  59. Díaz-Lagares C, Croca S, Sangle S, et al. Efficacy of rituximab in 164 patients with biopsy-proven lupus nephritis: pooled data from European cohorts. Autoimmun Rev 2012;11:357-364.
  60. Ramos-Casals M, Soto MJ, Cuadrado MJ, et al. Rituximab in systemic lupus erythematosus. A systematic review of off-label use in 188 cases. Lupus 2009;18:767-776.
  61. Furie R, Rovin BH, Houssiau F, Malvar A, Teng YKO, et al. Two-Year, Randomized, Controlled Trial of Belimumab in Lupus Nephritis. N Engl J Med 2020;383:1117-1128. doi: 10.1056/NEJMoa2001180
  62. Collins CE, Cortes-Hernandez J, Garcia MA, von Kempis J, Schwarting A, et al. Real-World Effectiveness of Belimumab in the Treatment of Systemic Lupus Erythematosus: Pooled Analysis of Multi-Country Data from the OBSErve Studies. Rheumatol Ther 2020;7:949-965. doi: 10.1007/s40744-020-00243-2
  63. Feng L, Deng J, Huo DM, Wu QY, Liao YH. Mycophenolate mofetil versus azathioprine as maintenance therapy for lupus nephritis: a meta-analysis. Nephrology (Carlton) 2013;18(2):104-10. doi: 10.1111/nep.12006. PMID: 23113811.
  64. Deng J, Xie H, Zhu L, Luo L, Xie H. Maintenance therapy for lupus nephritis with mycophenolate mofetil or azathioprine. A meta-analysis. Clin Nephrol 2019;91(3):172-179. doi: 10.5414/CN109450. PMID: 30686286.
  65. Hu W, Chen Y, Wang S, Chen Y, Liu Z, et al. Clinical–Morphological Features and Outcomes of Lupus Podocytopathy. Clin J Am Soc Nephrol 2016;11:585-592. doi: 10.2215/CJN.06720615
  66. Henderson LK, Masson P, Craig JC, et al. Induction and maintenance treatment of proliferative lupus nephritis: a meta-analysis of randomized controlled trials. Am J Kidney Dis 2013;61:74-87.
  67. Tunnicliffe DJ, Palmer SC, Henderson L, Masson P, Craig JC, Tong A, Singh- Grewal D, Flanc RS, Roberts MA, Webster AC, Strippoli GF. Immunosuppressive treatment for proliferative lupus nephritis. Cochrane Database Syst Rev 2018;6(6):CD002922. doi: 10.1002/14651858.CD002922.pub4. PMID: 29957821; PMCID: PMC6513226
  68. Kostopoulou M, Fanouriakis A, Cheema K, Boletis J, Bertsias G, et al. Management of lupus nephritis: a systematic literature review informing the 2019 update of the joint EULAR and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations. RMD Open 2020;6:e001263. doi: 10.1136/rmdopen-2020-001263
  69. Houssiau FA, D'Cruz D, Sangle S., et all. Azathioprine versus mycophenolate mofetil for long-term immunosuppression in lupus nephritis: results from the MAINTAIN Nephritis Trial. Ann Rheum Dis 2010;69(12):2083-2089.
  70. Chen W, Liu Q, Chen W, et al. Outcomes of maintenance therapy with tacrolimus versus azathioprine for active lupus nephritis: a multicenter randomized clinical trial. Lupus 2012;21:944-952.
  71. Zhang H, Liu Z, Zhou M, et al. Multitarget therapy for maintenance treatment of lupus nephritis. J Am Soc Nephrol 2017;28:3671-3678.
  72. Dooley MA, Jayne D, Ginzler EM, et al. Mycophenolate versus azathioprine as maintenance therapy for lupus nephritis. N Engl J Med 2011;365:1886-1895.
  73. Galbraith L, Manns B, Hemmelgarn B, et al. The steroids in the maintenance of remission of proliferative lupus nephritis (SIMPL) pilot trial. Can J Kidney Health Dis 2014;1:30.
  74. Moroni G, Longhi S, Giglio E, et al. What happens after complete withdrawal of therapy in patients with lupus nephritis. Clin Exp Rheumatol 2013;31:75-81
  75. Yap DY, Yu X, Chen XM, et al. Pilot 24 month study to compare mycophenolate mofetil and tacrolimus in the treatment of membranous lupus nephritis with nephrotic syndrome. Nephrology (Carlton) 2012;17:352-357.
  76. Tang K-T, Tseng C-H, Hsieh T-Y, et al. Induction therapy for membranous lupus nephritis: a systematic review and network meta-analysis. Int J Rheum Dis 2018;21:1163-1172.
  77. Deng J, Huo D, Wu Q, et al. A meta-analysis of randomized controlled trials comparing tacrolimus with intravenous cyclophosphamide in the induction treatment for lupus nephritis. Tohoku J Exp Med 2012;227:281-288.
  78. De Rosa M, Azzato F, Toblli JE, et al. A prospective observational cohort study highlights kidney biopsy findings of lupus nephritis patients in remission who flare following withdrawal of maintenance therapy. Kidney Int 2018;94:788-794
  79. Rovin BH, Furie R, Latinis K, et al. Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study. Arthritis Rheum 2012;64:1215-1226.
  80. Moroni G, Raffiotta F, Trezzi B, et al. Rituximab vs mycophenolate and vs cyclophosphamide pulses for induction therapy of active lupus nephritis: a clinical observational study. Rheumatology 2014;53:1570-1577
  81. Roccatello D, Sciascia S, Baldovino S, et al. A 4-year observation in lupus nephritis patients treated with an intensified B-lymphocyte depletion without immunosuppressive maintenance treatment: clinical response compared to literature and immunological re-assessment. Autoimmun Rev 2015;14:1123-1130.
  82. Sakthiswary R., D’Cruz D. Intravenous immunoglobulin in the therapeutic armamentarium of systemic lupus erythematosus: a systematic review and meta- analysis. Medicine (Baltimore) 2014;93(16):86. 10.1097/MD.0000000000000086.
  83. Furer V, Rondaan C, Heijstek MW, Agmon-Levin N, van Assen S, et al. 2019 update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis 2020;79:39-52. doi:10.1136/annrheumdis-2019-215882
  84. Devlin A, Waikar SS, Solomon DH, et al. Variation in initial kidney replacement therapy for end-stage renal disease due to lupus nephritis in the United States. Arthritis Care Res (Hoboken) 2011;63:1642-1653.
  85. Contreras G, Pagan J, Chokshi R, et al. Comparison of mortality of ESRD patients with lupus by initial dialysis modality. Clin J Am Soc Nephrol 2014;9:1949-1956.
  86. Jorge A, Wallace ZS, Lu N, et al. Renal transplantation and survival among patients with lupus nephritis: a cohort study. Ann Intern Med 2019;170:240
  87. Arnaud L, Mathian A, Ruffatti A, et al. Efficacy of aspirin for the primary prevention of thrombosis in patients with antiphospholipid antibodies: an international and collaborative meta-analysis. Autoimmun Rev 2014;13:281-291.
  88. Pengo V, Ruffatti A, Legnani C, et al. Clinical course of high-risk patients diagnosed with antiphospholipid syndrome. J Thromb Haemost 2010;8:237-242.
  89. Pengo V, Denas G, Zoppellaro G, et al. Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome. Blood 2018;132:13651371.
  90. Kronbichler A, Brezina B, Quintana LF, et al. Efficacy of plasma exchange and immunoadsorption in systemic lupus erythematosus and antiphospholipid syndrome: a systematic review. Autoimmun Rev 2016;15:38-49.
  91. Sciascia S, Radin M, Yazdany J, et al. Expanding the therapeutic options for renal involvement in lupus: eculizumab, available evidence. Rheumatol Int 2017;37:1249- 1255.
  92. Moroni G., Radice A., Giammarresi G. et al. Are laboratory tests useful for monitoring the activity of lupus nephritis? A 6-year prospective study in a cohort of 228 patients with lupus nephritis. Ann Rheum Dis 2009;68(2):234-237.
  93. Mosca M., Tani C., Aringer M., et al. European League Against Rheumatism recommendations for monitoring patients with systemic lupus erythematosus in clinical practice and in observational studies. Ann Rheum Dis 2010;69(7):1269-1274.
  94. Системная красная волчанка. Рациональная фармакотерапия ревматических заболевания. Под ред. В.А. Насоновой, Е.Л. Насонова. 2003. М. «Литтерра»:169-180.
  95. Соловьев С.К., Асеева Е.А., Попкова Т.В., Лила А.М., Мазуров В.И., Насонов Е.Л. Системная красная волчанка: новые горизонты диагностики и терапии. Научно-практическая ревматология. 2020;58(1):5–14
  96. Delate T., Hansen M.L., Gutierrez A.C., Le K.N. Indications for Rituximab Use in an Integrated Health Care Delivery System. J Manag Care Spec Pharm 2020;26(7):832- 838. 10.18553/jmcp.2020.26.7.832

Для продолжения работы требуется Регистрация
На предыдущую страницу

Предыдущая страница

Следующая страница

На следующую страницу
Список литературы
На предыдущую главу Предыдущая глава
оглавление
Следующая глава На следующую главу

Оглавление

Данный блок поддерживает скрол*